Adempas (generic name: riociguat) is prescribed to treat adults diagnosed with pulmonary arterial hypertension (PAH). It is also prescribed to patients with chronic thromboembolic pulmonary hypertension (CTEPH) who have been treated surgically but still have high pulmonary blood pressure or who cannot undergo surgery.
Adempas is a member of a class of drugs treated as guanylate cyclase (sGC) knocks that aim to keep blood vessels dilated. sGC is a naturally occurring chemical that interacts with nitric oxide (NO). Adempas increases sGC to increase traffic with NO. This has the effect of helping blood results from the blood vessels of the lung.
Adempas 0.5, 1, 1.5, 2 and 2.5 MG (42 Tablets) can improve the ability to exercise by lowering blood pressure (recorded in the standard 6-person walk), throttled by a certain amount and can help slow the progression of deterioration in physical conditions.
Adempas (Riociguat) is prescribed for the treatment of high blood pressure in the lungs (pulmonary hypertension) and contains the active ingredient riociguat. Riociguat is a stimulator of guanylate cyclase (sGC), which causes the pulmonary arteries (the blood vessels connecting the heart to the lungs) to widen. This lowers blood pressure in the lungs and makes it easier for the heart to pump blood through the lungs, which in turn results in an improvement in the ability to perform physical exercise.
Adempas is used to treat adult patients with chronic thromboembolic pulmonary hypertension (CTEPH) who cannot be operated on for this, or in patients who continue to have elevated blood pressure in the lungs after surgery or who develop elevated blood pressure in the lungs again.
In addition, Adempas is used for certain forms of pulmonary arterial hypertension (PAH), namely in idiopathic PAH (the cause of the PAH is unknown), hereditary PAH and PAH caused by connective tissue disease.
This is a medicine, with no long-term use without medical advice, keep out of reach of children, read the package insert carefully. Get advice from your doctor or pharmacist. In case of side effects, contact your doctor.
Medicines are not ordinary products. They can never be returned or exchanged. The law prohibits pharmacists from taking back unused medicines. In the interest of your safety, all medicines you return to the pharmacy will be sorted with expired medicines.
Active substance: Riociguat (soluble guanylate cyclase stimulator)
Indications:
- Chronic thromboembolic pulmonary hypertension (CTEPH): Narrowing of the pulmonary arteries by blood clots
- Certain forms of pulmonary arterial hypertension (PAH): Thickening and narrowing of the walls of the pulmonary arteries
Dosage Type | Dosage | Frequency | Duration |
---|---|---|---|
Initial Dose | 1 mg | 3 times daily | 2 weeks |
Maintenance Dose | 1.5 mg to 2.5 mg | 3 times daily | As prescribed by the doctor |
Individual Adjustment | As per doctor’s advice | – | – |
Side effects:
- Common: Headache, dizziness, digestive disorders, edema, diarrhea, nausea, vomiting
- Occasional: Inflammation of the gastrointestinal tract, anemia, heart palpitations, low blood pressure, nosebleeds, breathing difficulties, stomach pain, heartburn, difficulty swallowing, constipation, bloating
- Rare: Bloody cough, sudden lung bleeding
Contraindications:
- Taking PDE-5 inhibitors (sildenafil, tadalafil, vardenafil)
- Severe liver dysfunction
- Allergy to riociguat or any other component of the drug
- Pregnancy
- Taking nitrates or nitric oxide donors
- Taking other soluble guanylate cyclase stimulators
- Low blood pressure before starting treatment
- Pulmonary hypertension with idiopathic pulmonary pneumonia
Special notes:
- Use only under medical supervision.
- Regular blood pressure monitoring during treatment..
- Caution in patients with renal or hepatic impairment, elderly patients, smokers, patients with low blood pressure, or certain concomitant diseases.
- Avoid taking certain medications at the same time.
- Women of childbearing age must use contraception during treatment.
- Breastfeeding is not allowed during treatment.
Road traffic safety:
- The drug may cause dizziness and impair driving ability.
- Caution when driving and operating machinery.
USE: Treatment of pulmonary hypertension (PH) in adults and children aged 6 years and older
Reviews
There are no reviews yet.